Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Not Applicable

Recruiting

• Conditions: Fatty Liver
• Interventions: Other: wet cupping; Device: laser acupuncture

• Registration Number: NCT05623930
• Lead Sponsor: Cairo University

Brief Summary

fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)

Detailed Description

In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints

Study Timeline

• Study Start: 2022-10-12
• Status Verified: 2022-11
• Study First Submitted: 2022-11-14
• Study First Submitted QC: 2022-11-18
• Last Update Submitted: 2022-11-18
• Study First Posted: 2022-11-21
• Last Update Posted: 2022-11-21
• Primary Completion: 2023-04-01
• Study Completion: 2023-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• fatty liver obese patients

Exclusion Criteria

thoracic diseases heart diseases kidney diseases

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
cupping (with scarification)	wet cupping	in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
laser on acupuncture points	laser acupuncture	In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian

Primary Outcome Measures

Name	Time	Method
high density lipoprotein	12 weeks	it is a component of lipid profile

Secondary Outcome Measures

Name	Time	Method
cholesterol	12 weeks	it is a component of lipid profile
blood glucose	12 weeks	fasting level of blood glucose will be measured
diastolic blood pressure	12 weeks	it will be measured by sphygmomanometer
systolic blood pressure	12 weeks	it will be measured by sphygmomanometer
Malondialdehyde	12 weeks	it ts oxidative stress marker
low density lipoprotein	12 weeks	it is a component of lipid profile
triglycerides	12 weeks	it is a component of lipid profile
C reactive protein	12 weeks	high sensitivity levels C reactive protein will be measured
aspartate transaminase	12 weeks	it is a hepatic enzyme that reports the functions of liver
alanine transaminase	12 weeks	it is a hepatic enzyme that reports the functions of liver
pulse rate	12 weeks	it will be measured manually

Trial Locations

Locations (1)

Cairo Unoversity; 🇪🇬 Giza, Egypt